•   
  •   
  •   

Health Alzheimer: A new drug proven itself

02:50  02 october  2022
02:50  02 october  2022 Source:   medisite.fr

The Worst Drinking Habit Aging Your Brain Faster, New Study Finds

  The Worst Drinking Habit Aging Your Brain Faster, New Study Finds You may want to cut or reduce your alcohol consumption, as a recent study has found that this drinking habit may be aging your brain faster. In the July 2022 study, published in PLOS Medicine, researchers collected data from 20,965 participants whose mean age was 55. While 2.7% of those involved didn't drink any alcohol, the remaining participants were drinking an average of 18 units every week. To put that into perspective, 18 units is about the same as six sizable glasses of wine. If you prefer beer, then you'll be interested to know that it's the same as seven and a half cans of your favorite brew.

Alzheimer : un nouveau médicament fait ses preuves © Adobe Stock Alzheimer: a new medication proves

science is about to find the drug capable of slowing down the disease? The latest clinical trials are intended to be even more encouraging than expected ...

A pharmaceutical group, bringing together Japanese S Cientifiques from the Eisai laboratory and American experts from Biogen, have made a revelation imprint for the future: The treatment they have developed, responding to the name of Lecanemab , has proven itself during the last clinical trials carried out.

The Cognitive Decline considerably slowed down

is therefore a most delightful revelation that marked the day of September 28: the group of experts said he was "encouraged" by the results obtained within the framework of the tests of their new drug developed against Alzheimer . These positive returns make the drug concerned, the first in the list to have proven its role in the slowdown in the progression of Alzheimer's disease.

Leading Alzheimer’s theory undermined: Did tampering waste 16 years of research?

  Leading Alzheimer’s theory undermined: Did tampering waste 16 years of research? Sylvain Lesné's landmark 2006 study that pointed to a cause of Alzheimer's may have been doctored, calling into question whether years of research and funding were wasted.The allegations centre around a landmark 2006 study — a paper which has been cited nearly 2,300 times — whose findings identify a protein called amyloid beta as a cause of Alzheimer's. Since then, the hypothesis that sticky deposits of amyloid beta form plaques in the brain that slow cognition has dominated Alzheimer's research and treatment development.

The LecaneMab would have reached, according to the researchers, to slow down by 27 % the cognitive and functional decline specific to the disease, in comparison with the results obtained with a placebo. 1,800 patients were studied as part of this work: the experimental treatment was administered to half the group, the other part having received an placebo . The reduction in the decline of cognitive functions was recorded over an 18 -month period .

Alzheimer: towards the hope of a treatment

In view of the very encouraging results, The Laboratoires Biogen and Eisai at the origin of the drug plan to file the requests which will subsequently allow the drug to be authorized The sale, thus marketing the treatment through the United States, Europe then Japan during the month of March 2023.

neuroscientists discover the presence of dementia in the brain very close to Alzheimer

 neuroscientists discover the presence of dementia in the brain very close to Alzheimer © provided by Gentside a new brain disease similar to Alzheimer has just been discovered during a study carried out by neuroscientists from the University of Kentucky in the United States in 2019, the latter discovered the presence of dementia in neurons called Late . A new disease still unknown, but which is very close to of the symptoms of Alzheimer . Often present in octogenarians, this dementia was found in 40% of patients analyzed for this study.

"If the data resists an in-depth examination, this is a new Fantastic, "said Tara Spires-Jones, researcher at the University of Edinburgh, before recalling that if the treatment does not lead" an heighting ", he can still" brake the Cognitive Cognitive and thus preserving the possibility of carrying out normal daily activities is already a huge victory ”. Medication: side effects to be monitored

, however, if these results remain encouraging for the future and have been welcomed by

the scientific community , they will have to be the subject of more research and test phases, "In view of the risks side effects, including inflammation and bleeding in the brain , "said Dr. Charles Marshall, expert from the Queen Mary University of London.

The Lecanemab medication was developed to act on the

protein plates found in Alzheimer's patients, although the scientist community does not yet know their Role exact. Indeed, when they intervene, these plates cling to neurons and end up destroying them: but are they the very cause of the development of the disease, or are they the consequence? A mystery that researchers intend to quickly elucidate.

For Professor Dubois, neurologist at the Pitié-Salpêtrière hospital, “The results of LecaneMab are positive and indisputable . The study is powerful and has been well conducted, on patients at stages less advanced than for the ADUCANUMAB. We have proof that when we act on amyloid lesions, there is then an effect on Symptoms , "he told Sciences et Avenir media.

Hear from the experts on Brazil nut, plus health benefits, and recipes .
Hear from the experts on Brazil nut, plus health benefits, and recipes

usr: 1
This is interesting!